Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.413 - Diagnostic Value of the Basophil Degranulation Test in High-Risk Drug-Induced Anaphylaxis
D2.415 - DRESS Syndrome induced by Lenalidomide
D2.407 - Treating Through in Pediatric Patients: A Single-Center Experience
D2.408 - Hypersensitivity Reactions to Corticosteroids: A Retrospective Cohort Study
D2.414 - Diagnostic Distribution of Patch, Delayed-Reading Intradermal, and Drug Provocation Tests in Delayed-Type Cutaneous Drug Hypersensitivity
D2.416 - Skin reaction to Kaftrio/Kalydeco (CFTR) in cystic fibrosis: safe reintroduction using an outpatient desensitization protocol
D2.418 - Tolperisone Hypersensitivity: An Underrecognized Drug Allergy in the Context of Widespread Off-Label Use
D2.419 - DRESS syndrome in the context of carbamazepine treatment - case report
D2.420 - A challenging case of cardiotoxicity following palbociclib therapy
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome
D2.460 - Does Aspirin change outcomes of dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download